China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the Health Sciences Authority (HSA) in Singapore to conduct a Phase I clinical study for its investigational drug, 177Lu-LNC1003.
177Lu-LNC1003: A Radiopharmaceutical for Advanced Prostate Cancer
177Lu-LNC1003 is a radioactive in vivo therapeutic drug that targets prostate specific membrane antigen (PSMA), designed for the treatment of advanced prostate cancer with PSMA expression. The drug has demonstrated high binding affinity and PSMA targeting specificity in both in vivo and in vitro animal experiments, as well as in investigator initiated trials (IITs).- Flcube.com
